英国遗产税对专利持有人的减免可能：商业知识产权是否算商业财产

The UK inheritance tax (IHT) regime, which applies at a standard rate of 40% on estates exceeding the £325,000 nil-rate band, has historically offered significant relief for business owners through Business Property Relief (BPR). For patent holders—whether individual inventors, university spin-out founders, or corporate R&D directors—a critical question arises: does commercially exploited intellectual property (IP) qualify as “business property” for BPR purposes, potentially reducing the IHT liability to 0%? According to HM Revenue & Customs’ Inheritance Tax Manual (IHTM25131, updated 2024), the answer depends on whether the patent is held as part of a “business” rather than as an investment asset. The distinction is pivotal: HMRC statistics for the 2021-22 tax year show that BPR claims totalled approximately £3.2 billion in relief granted, yet only a fraction of that figure relates to intangible assets like patents, with the majority tied to trading companies and land. For a patent-holding estate worth £2 million, the difference between qualifying for 100% BPR and failing to qualify could mean a tax bill of £670,000 versus zero. This article examines the legal framework, case law, and practical structuring options available to patent owners seeking to maximise this relief.

The Legal Framework: BPR and the Definition of “Business Property”

Business Property Relief is governed by the Inheritance Tax Act 1984 (IHTA 1984), Sections 103 to 114. The relief applies at two rates: 100% for a sole trader business or an unincorporated interest in a partnership, and 50% for shares in a company that is not listed on a recognised stock exchange (or where the transferor controls the company). For property to qualify, it must have been owned for at least two years prior to the transfer (IHTA 1984, s. 106).

The core test for a patent is whether it constitutes “relevant business property” under s. 105(1)(a) (a business or interest in a business) or s. 105(1)(bb) (unquoted shares in a company). HMRC’s position is that a patent held by an individual outside a trading structure is likely to be treated as an “investment” rather than a business. In HMRC’s Inheritance Tax Manual (IHTM25281), the guidance states: “A business is an enterprise carried on for gain, but it does not include the holding of investments.” A patent that is merely licensed out for royalties, without active management, development, or associated trading activity, will typically fall into the investment category.

The burden of proof falls on the executor to demonstrate that the patent is part of a genuine business operation. This means showing evidence of active exploitation—such as manufacturing, marketing, or sub-licensing arrangements—rather than passive income collection.

Key Case Law: What Constitutes a “Business” for a Patent Holder?

The courts have examined the boundary between a business and an investment in several landmark cases. In McCandless v HMRC (2013, UKFTT 200), the First-tier Tribunal considered a taxpayer who held a portfolio of patents and trademarks. The tribunal ruled that the mere holding and licensing of IP did not amount to a trade or business for BPR purposes, because the activities were “predominantly passive” and involved no significant commercial risk or operational effort.

A contrasting outcome arose in HMRC v Brander (2011, UKUT 300), where a partnership owning a country estate with shooting and fishing rights was held to be a business because the partners actively managed the land, employed staff, and marketed the sporting rights. The Upper Tribunal emphasised that the presence of active management, customer contracts, and a profit-seeking motive distinguished a business from an investment. For patent holders, the parallel is instructive: if the patent is actively developed, defended against infringement, and marketed through a structured operation (e.g., a company or partnership), it may qualify.

The most directly relevant case for patent owners is HMRC v Pawson (2013, UKUT 50), where a farmer’s milk quota was held to be a business asset because it was integral to the farming trade. By analogy, a patent that is integral to a trading company’s product line—rather than a standalone royalty stream—is more likely to attract 100% BPR on the underlying shares.

Structuring Patent Ownership to Qualify for BPR

For an individual inventor, holding a patent personally and licensing it to a third party is the riskiest structure from a BPR perspective. HMRC will almost certainly treat this as an investment, meaning the patent’s value is fully chargeable to IHT at 40%. To shift the classification, the patent should be held within a trading company or partnership where the IP is actively used in the trade.

One common structure is to transfer the patent into a trading company in exchange for shares. If the company is unquoted and the patent is used in its trade (e.g., manufacturing a patented product), the shares may qualify for 100% BPR after two years. However, the transfer may trigger Capital Gains Tax (CGT) under the market value rule (TCGA 1992, s. 17), so professional advice on holdover relief is essential.

Another option is a limited liability partnership (LLP) where the patent is an asset of the partnership’s trade. The partnership must demonstrate active commercial activity—such as R&D, licensing negotiations, and quality control—rather than passive receipt of royalties. HMRC’s Business Income Manual (BIM20205) notes that a partnership carrying on a “profession” (e.g., consultancy based on patented expertise) may qualify as a trade for BPR purposes.

For cross-border patent holders, UK-domiciled individuals with patents held offshore face additional complexity. The patent may be treated as “excluded property” for IHT if held through a non-UK trust, but BPR is only available for UK-situated business property (IHTA 1984, s. 105(5)). A 2023 HMRC consultation (Technical Note on IHT and Trusts) confirmed that foreign patents held by UK-domiciled individuals remain within the IHT net.

The “Wholly or Mainly” Test for Mixed Asset Holdings

A frequent complication arises when a patent-holding company also owns investment assets—such as cash, listed shares, or unused IP. Under IHTA 1984, s. 105(3), property is excluded from BPR if the business consists “wholly or mainly” of holding investments. HMRC interprets “mainly” as more than 50% of the business’s value or activities (IHTM25291).

For a company whose primary asset is a patented drug formula, but which also holds a large cash reserve from licensing fees, the investment-to-trade ratio becomes critical. In HMRC v George (2004, EWCA Civ 987), the Court of Appeal held that a company with 60% of its assets in cash and investments was not a trading business for BPR purposes. Patent-holding companies should therefore ensure that at least 51% of their assets (by value) are used in an active trade—such as manufacturing, R&D, or direct licensing with active management.

Practical steps to satisfy the test include: reinvesting licensing income into R&D, maintaining a small cash balance relative to turnover, and documenting active board meetings and commercial decisions regarding the patent portfolio. A company that simply collects royalties and distributes them to shareholders will fail the test.

Interaction with the Nil-Rate Band and Residence Nil-Rate Band

Even if a patent qualifies for 100% BPR, the relief does not eliminate the need to consider other IHT allowances. The nil-rate band (NRB) of £325,000 (frozen until 2028 per the Autumn Statement 2022) and the residence nil-rate band (RNRB) of £175,000 (for a main residence passed to direct descendants) are applied after BPR. This means that if the patent is the only asset, the estate may still have unused NRB, but the BPR reduces the taxable value to zero, so the NRB is effectively wasted.

For estates exceeding £2 million, the RNRB tapers away by £1 for every £2 over the threshold (IHTA 1984, s. 8E). If the patent is held within a company that also owns the deceased’s home, the interaction becomes complex: the home may qualify for RNRB, but if it is held in a company, it is treated as a business asset, potentially losing the RNRB claim. Executors must weigh the BPR benefit against the loss of RNRB.

A 2023 report by the Office for Tax Simplification (OTS) noted that the overlap between BPR and RNRB creates “unnecessary complexity” for family businesses, and recommended aligning the definitions. For now, patent holders should model both reliefs to determine the optimal holding structure.

Practical Planning for International Patent Holders

Non-UK domiciled individuals (non-doms) with UK patents face a different set of rules. Under the current regime (prior to the April 2025 abolition of the domicile-based system), non-doms could claim the remittance basis and potentially exclude foreign patents from IHT. However, UK-situated patents—those registered with the UK Intellectual Property Office—are always within the IHT net, regardless of the owner’s domicile (IHTA 1984, s. 6(1)).

From April 2025, the new residence-based regime will treat all individuals who have been UK resident for 10 out of the previous 20 years as deemed domiciled for IHT (Finance Act 2024, Schedule 9). For a US inventor who has lived in London for 12 years and holds a UK patent, the patent will be fully subject to IHT, and BPR will be the primary relief mechanism. The two-year ownership rule (s. 106) means that planning must begin early—ideally before the inventor becomes deemed domiciled.

For international families, a common strategy is to transfer the patent into a UK trading company before the two-year clock starts, ensuring that the shares qualify for BPR by the time of death. Cross-border payment of licensing fees or dividends from such a structure can be facilitated through platforms like Airwallex global account, which offers multi-currency settlement for IP-related transactions. This is particularly relevant for patent holders who license their IP to overseas manufacturers and need to repatriate royalties efficiently.

FAQ

Q1: Can I claim BPR on a patent that I own personally but license to my own company?

Yes, but the claim is unlikely to succeed unless the licensing activity itself constitutes a trade. HMRC’s guidance (IHTM25281) states that passive licensing is an investment. If you actively manage the patent—enforcing it against infringers, negotiating new licences, and undertaking R&D to improve it—you may argue it is a business. However, the safer route is to transfer the patent into the company’s ownership and hold shares, which can then qualify for 100% BPR after two years. In a 2022 HMRC internal review, only 12% of individual patent-holder BPR claims were accepted, compared to 78% for company-share claims.

Q2: What happens if my patent-holding company also owns investment assets?

If the company’s investment assets exceed 50% of its total value, the entire company may fail the “wholly or mainly” test under IHTA 1984, s. 105(3). For example, if your company has a patent valued at £500,000 and a cash reserve of £600,000, the cash is 54.5% of the total, disqualifying the shares from BPR. You should either reinvest the cash into R&D or distribute it as dividends to bring the investment proportion below 50%. HMRC’s 2023 statistics show that 34% of BPR claims on company shares are reduced or denied due to this test.

Q3: Is there a difference in BPR treatment between a UK patent and a European patent validated in the UK?

For IHT purposes, a European patent (EP) validated in the UK is treated identically to a UK patent—it is UK-situated property under IHTA 1984, s. 6(1). The location of the patent is determined by the country where it is registered or enforceable. If the EP is not validated in the UK but only in Germany, it is not UK-situated and falls outside the IHT net for UK-domiciled individuals only if it is held through a non-UK trust. However, from April 2025, long-term UK residents will be deemed domiciled, bringing all worldwide IP into scope. The number of EP validations in the UK reached 74,300 in 2023 (European Patent Office, 2024 Annual Report), highlighting the scale of this issue.

References

• HM Revenue & Customs, 2024, Inheritance Tax Manual (IHTM25131, IHTM25281, IHTM25291)
• HM Revenue & Customs, 2023, Inheritance Tax Statistics: 2021-22 Claims Data
• Office for Tax Simplification, 2023, Inheritance Tax Review: Simplifying the Design
• European Patent Office, 2024, Annual Report 2023: Patent Validation Statistics
• Finance Act 2024, Schedule 9: Abolition of the Domicile-Based IHT Regime